A correct patient risk stratification is of paramount importance for the proper management of economic and human resources.
Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage.
Controlled studies may highlight a potential preventive role of immunosuppressant in the development of Covid-19 severe forms
Despite the risk of infection in rheumatic and gastroenterological diseases a conclusive link with COV-19 remains questionable
Keywords: COVID-19; DMARDs; Flow-chart; Infection; Inflammatory bowel disease; Prevention; Rheumatic disease; Small molecules; Treatment; bDMARDs.